|[March 05, 2013]
Research and Markets: PharmaPoint: HIV - United Kingdom Drug Forecast and Market Analysis to 2022
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/knsqzv/pharmapoint_hiv)
has announced the addition of GlobalData's new report "PharmaPoint: HIV
- United Kingdom Drug Forecast and Market Analysis to 2022" to their
GlobalData has released its new Country report, PharmaPoint: HIV -
United Kingdom Drug Forecast and Market Analysis to 2022. Human
Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed
millions of lives since its emergence. However, the advent of
antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a
deadly disease to a manageable chronic condition for most infected
individuals. Antiretroviral treatment not only reduces the viral load
and reconstitutes immune function, bt also decreases infection
incidence rates by limiting viral transmission. The treatment algorithm
in HIV has characteristically involved multiple drug regimens designed
to tackle the virus on different levels. In the recent past, simplified
dosing regimens through the emergence of single tablet regimens (STRs)
or fixed dose combination (FDC) therapies have become increasingly
popular amongst physicians and patients alike by increasing clinical
efficacy thresholds and enabling patient compliance.
As in the US, several STRs are expected to be released during the
forecast period, overthrowing Atripla from its position of prominence.
As a whole, the combined market share of STRs will be affected by key
patent expiries, such as those of BMS' Sustiva, a key component of
Atripla. Combined with healthcare budget restrictions imposed by the
general financial situation in Europe, this might lead to a drastic drop
in Atripla sales, with newer STRs facing a higher barrier to entry into
the UK market.
- Overview of the United Kingdom including epidemiology, etiology,
symptoms, diagnosis, pathology and treatment guidelines as well as an
overview on the competitive landscape.
- Sales forecast for the top drugs in the United Kingdom from 2012-2022.
- Analysis of the impact of key events as well the drivers and
restraints affecting the United Kingdom HIV market.
For more information visit http://www.researchandmarkets.com/research/knsqzv/pharmapoint_hiv
Source (News - Alert): GlobalData
[ InfoTech Spotlight's Homepage ]